Physician profile
Robert Ward Selfe
NPI 1003038605
$238,201.35
in general payments reported to CMS, 2019-2025
12 companies · $68K in 2025
The $68K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $225 · 2021: $40K · 2022: $63K · 2023: $31K · 2024: $37K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $42K · Travel and Lodging: $12K · Food and Beverage: $7,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,964.27 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $42,030.00 |
| Travel and Lodging | $11,848.73 |
| Food and Beverage | $7,072.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $155,496.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $63,115.53 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $17,540.67 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $810.82 | 2021-2025 | Minimed 780g |
| Lilly USA, LLC | $409.67 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $242.50 | 2021-2024 | Freestyle Libre 3 |
| Sequel Med Tech, LLC | $151.56 | 2025 | Twiist |
| Beta Bionics, INC. | $137.86 | 2023 | Ilet Bionic Pancreas |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.36 | 2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $80.20 | 2019-2023 | |
| Medtronic Minimed, INC. | $54.22 | 2019-2020 | |
| Insulet Corporation | $41.42 | 2019-2023 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Selfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.